{"anticipatedPostingDate":"2026-09","denomUnitsSelected":"Participants","description":"PFS2 defined as time from date of randomization to the first documented progression by investigator's assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first, on next-line of therapy. Next-line therapy was defined as the first new (systemic) anti-neoplastic therapy initiated after discontinuation of study treatment regardless of end of treatment (EoT) reason.","reportingStatus":"NOT_POSTED","timeFrame":"From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to approx. 32 months","title":"Second Progression Free Survival (PFS2) by Investigator's Assessment","type":"SECONDARY"}